Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00763620
Other study ID # P080502
Secondary ID
Status Completed
Phase N/A
First received September 30, 2008
Last updated September 22, 2011
Start date February 2009
Est. completion date June 2011

Study information

Verified date June 2011
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

The aim of this study is to develop a safe and effective technique to take sample for lower respiratory tract cultures easy to perform in conditions of acute respiratory failure and spontaneous ventilation for patients admitted in intensive care unit for acute infectious pneumonia and non intubated. The investigators perform sample collection with a mini bronchoalveolar lavage catheter introduced by nasotracheal way through a suction catheter. The purpose of the study is to assess the microbiological diagnostic capacity of this new technique.


Description:

At the moment we lack an effective and safe technique to obtain lower respiratory tract cultures for patient with mild serious infectious pneumonia admitted in intensive care unit and non intubated. Invasive procedure may worsen respiratory distress and non invasive procedure such expectorated sputum culture is not enough effective. The purpose of the study is to assess the microbiological diagnosis capacity of a new technique for taking samples from the lower respiratory tract: mini bronchoalveolar lavage performed by naso tracheal way through a suction catheter.Each consecutive patient admitted in intensive care unit for a community acquired or nosocomial pneumonia and not requiring intubation and mechanical ventilation will be included. Written informed consent by patient himself will be required. For each patient, after the introduction of a suction catheter, an endotracheal aspiration will be performed. Then, the mini bronchoalveolar lavage will be performed through the suction catheter with a specific catheter.The whole time of the procedure is about ten minutes.Expectorated sputum will also be ordered for each patient.This study is a pilot and prospective study.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date June 2011
Est. primary completion date June 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age over 18

- Radiological diagnosis of pneumonia (community acquired or nosocomial)

- No microbiological diagnosis known

- Indication for culture of lower respiratory tract

- Admission in intensive care unit required

Exclusion Criteria:

- Age lower than 18

- Bronchospasm

- Coagulopathy ( Platelets count below 100 000/mm3, prothrombin time less than 50%, activated partial thromboplastin time ratio higher than 2)

- Intubation with mechanical ventilation

- Known microbiological diagnosis

- Incapacity for consenting himself to the study

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Device:
catheter for mini bronchoalveolar lavage
For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.

Locations

Country Name City State
France Dr Pascal MEYER Corbeil Ile de France

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris PLASTIMED Laboratory

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome measure is the rate of positive microbiological culture one year No
Secondary Comparison between rate of positive culture obtain with mini bronchoalveolar lavage and the two others techniques used in the sudy: endotracheal aspiration and expectorated sputum one year No
Secondary Feasibility of the procedure ten minutes No
Secondary The acceptance of the procedure ten minutes Yes
Secondary Physiological variables: heart and respiratory rate, oxygen saturation, blood pressure before procedure and fifteen minutes after procedure Yes
Secondary If applicable: complications of the procedure one day Yes
Secondary Time to obtain the result of the culture one day one day No
Secondary Time of the procedure one day No
See also
  Status Clinical Trial Phase
Terminated NCT01570192 - Clinical Trials to Reduce the Risk of Antimicrobial Resistance Phase 2
Recruiting NCT04952337 - Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
Completed NCT02493764 - Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) Phase 3
Completed NCT02531438 - Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13) Phase 3
Completed NCT00079885 - Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia Phase 3
Recruiting NCT05629741 - A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101 Phase 1
Completed NCT05417997 - Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients Phase 3
Withdrawn NCT00645619 - Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children
Completed NCT00509106 - Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia Phase 3
Completed NCT00080496 - Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia Phase 3
Completed NCT03158727 - Cx611-0204 SEPCELL Study Phase 1/Phase 2
Completed NCT00621504 - Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia Phase 3
Completed NCT00124020 - Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Phase 3
Completed NCT00081575 - Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia Phase 3
Completed NCT00451386 - Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036) Phase 2
Recruiting NCT03752320 - Multiplex Polymerase Chain Reaction in Postoperative Pneumonia After Thoracic Surgery
Active, not recruiting NCT04779242 - Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia Phase 3
Completed NCT00107952 - Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Phase 3
Terminated NCT03862040 - Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia Phase 1
Recruiting NCT05531149 - Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia Phase 3